Overview

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Status:
Recruiting
Trial end date:
2030-12-30
Target enrollment:
0
Participant gender:
All
Summary
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tanta University
Treatments:
Alverine
Ethosuximide
Mebeverine
Pentoxifylline
Criteria
Inclusion Criteria:

- • Age ≥ 18 years,

- Man and Women, Negative pregnancy test and effective contraception,

- IBS defined by the Rome criteria IV

- During the previous seven days the inclusion visit, average numeric rating scale
(NRS) pain ≥ 4.

- IBS Treatment stable for 1 month

Exclusion Criteria:

- • Breastfeeding

- Diabetic patients

- Significant liver function abnormalities (transaminases> 3N, cholestasis) and
moderate renal disease (MDRD <60 ml / min)

- Addiction to alcohol and / or drugs,

- Antiepileptic drugs taken (epilepsy or chronic pain)

- Chronic pain of greater intensity than that related to IBS,

- Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and
pentoxifylline.

- History or current severe depression (hospitalization, long-term antidepressant
treatment)

- Psychotic disorders,